Praxis Precision Medicines (PRAX) Income towards Parent Company (2019 - 2026)
Praxis Precision Medicines (PRAX) posted quarterly Income towards Parent Company of -$562.1 million for Q1 2026, down 641.16% year-over-year from $103.9 million in Q1 2025, and down 10.87% quarter-over-quarter from -$507.0 million in Q4 2025.
Praxis Precision Medicines (PRAX) Income towards Parent Company (2019 - 2026) Analysis & Trends
Praxis Precision Medicines' Income towards Parent Company history runs 8 years deep, the most recent figure standing at -$562.1 million for Q1 2026.
- In Q1 2026, Income towards Parent Company fell 641.16% year-over-year to -$562.1 million; the TTM figure through Mar 2026 stood at -$1.2 billion (down 165.03% YoY), while the FY2025 annual figure was -$736.1 million, down 75.91% from the prior year.
- Income towards Parent Company for Q1 2026 stood at -$562.1 million, down from -$507.0 million in the prior quarter.
- The five-year high for Income towards Parent Company was -$25.7 million in Q3 2023, with the low at -$562.1 million in Q1 2026.
- The 5-year median for Income towards Parent Company is -$75.8 million (2025), against an average of -$143.2 million.
- The sharpest annual moves came in 2023 and 2026: Income towards Parent Company surged 54.43% in 2023, then tumbled 641.16% in 2026.
- Praxis Precision Medicines' Income towards Parent Company stood at -$184.1 million in 2022, then fell by 13.17% to -$208.3 million in 2023, then sank by 35.5% to -$282.3 million in 2024, then sank by 79.62% to -$507.0 million in 2025, then decreased by 10.87% to -$562.1 million in 2026.
- Business Quant data shows PRAX's Income towards Parent Company at -$562.1 million in Q1 2026, -$507.0 million in Q4 2025, and -$87.0 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Praxis Precision Medicines | 10.24 Bn | 9.48 Bn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -564.12 Mn |
| Mar 31, 2026 | -562.09 Mn |
| Dec 31, 2025 | -506.98 Mn |
| Sep 30, 2025 | -87.02 Mn |
| Jun 30, 2025 | -77.90 Mn |
| Mar 31, 2025 | -75.84 Mn |
| Dec 31, 2024 | -282.26 Mn |
| Sep 30, 2024 | -68.23 Mn |
| Jun 30, 2024 | -39.27 Mn |
| Mar 31, 2024 | -56.08 Mn |
| Dec 31, 2023 | -208.31 Mn |
| Sep 30, 2023 | -25.74 Mn |
| Jun 30, 2023 | -35.01 Mn |
| Mar 31, 2023 | -37.96 Mn |
| Dec 31, 2022 | -184.07 Mn |
| Sep 30, 2022 | -43.95 Mn |
| Jun 30, 2022 | -61.22 Mn |
| Mar 31, 2022 | -83.31 Mn |
| Dec 31, 2021 | -58.58 Mn |
| Sep 30, 2021 | -44.71 Mn |